New antipsychotic agents

Emerging clinical profiles

Peter F. Buckley

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The past 5 years have witnessed an intense period of change in the pharmacotherapy of schizophrenia. Several new antipsychotic agents have become available for clinical use, and more are likely to appear over the next few years. The new agents require that clinicians treating patients with schizophrenia adopt new ways of thinking regarding the pharmacotherapy of this illness. Longer drug trials than have traditionally been used may be required to determine response to the newer agents, and response should be measured across negative symptoms, cognitive symptoms, and broader rehabilitative dimensions. Clozapine has an established role in treatment- resistant schizophrenia. Other new antipsychotics are being used with broader clinical indications. The relative efficacy of these agents, particularly in treatment-refractory patients, remains to be determined. The availability of the newer agents may represent an opportunity to reduce the incidence of tardive dyskinesia and to gain better management of comorbid substance abuse and aggression among schizophrenic patients. Significant cost savings could accrue from more effective disease management.

Original languageEnglish (US)
Pages (from-to)12-17
Number of pages6
JournalJournal of Clinical Psychiatry
Volume60
Issue numberSUPPL. 1
StatePublished - Feb 16 1999

Fingerprint

Antipsychotic Agents
Schizophrenia
Drug Therapy
Neurobehavioral Manifestations
Cost Savings
Clozapine
Disease Management
Aggression
Substance-Related Disorders
Incidence
Therapeutics
Pharmaceutical Preparations
Tardive Dyskinesia
Thinking

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

New antipsychotic agents : Emerging clinical profiles. / Buckley, Peter F.

In: Journal of Clinical Psychiatry, Vol. 60, No. SUPPL. 1, 16.02.1999, p. 12-17.

Research output: Contribution to journalArticle

Buckley, PF 1999, 'New antipsychotic agents: Emerging clinical profiles', Journal of Clinical Psychiatry, vol. 60, no. SUPPL. 1, pp. 12-17.
Buckley, Peter F. / New antipsychotic agents : Emerging clinical profiles. In: Journal of Clinical Psychiatry. 1999 ; Vol. 60, No. SUPPL. 1. pp. 12-17.
@article{d28eb080439842cb849548df3a6cad0f,
title = "New antipsychotic agents: Emerging clinical profiles",
abstract = "The past 5 years have witnessed an intense period of change in the pharmacotherapy of schizophrenia. Several new antipsychotic agents have become available for clinical use, and more are likely to appear over the next few years. The new agents require that clinicians treating patients with schizophrenia adopt new ways of thinking regarding the pharmacotherapy of this illness. Longer drug trials than have traditionally been used may be required to determine response to the newer agents, and response should be measured across negative symptoms, cognitive symptoms, and broader rehabilitative dimensions. Clozapine has an established role in treatment- resistant schizophrenia. Other new antipsychotics are being used with broader clinical indications. The relative efficacy of these agents, particularly in treatment-refractory patients, remains to be determined. The availability of the newer agents may represent an opportunity to reduce the incidence of tardive dyskinesia and to gain better management of comorbid substance abuse and aggression among schizophrenic patients. Significant cost savings could accrue from more effective disease management.",
author = "Buckley, {Peter F.}",
year = "1999",
month = "2",
day = "16",
language = "English (US)",
volume = "60",
pages = "12--17",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - New antipsychotic agents

T2 - Emerging clinical profiles

AU - Buckley, Peter F.

PY - 1999/2/16

Y1 - 1999/2/16

N2 - The past 5 years have witnessed an intense period of change in the pharmacotherapy of schizophrenia. Several new antipsychotic agents have become available for clinical use, and more are likely to appear over the next few years. The new agents require that clinicians treating patients with schizophrenia adopt new ways of thinking regarding the pharmacotherapy of this illness. Longer drug trials than have traditionally been used may be required to determine response to the newer agents, and response should be measured across negative symptoms, cognitive symptoms, and broader rehabilitative dimensions. Clozapine has an established role in treatment- resistant schizophrenia. Other new antipsychotics are being used with broader clinical indications. The relative efficacy of these agents, particularly in treatment-refractory patients, remains to be determined. The availability of the newer agents may represent an opportunity to reduce the incidence of tardive dyskinesia and to gain better management of comorbid substance abuse and aggression among schizophrenic patients. Significant cost savings could accrue from more effective disease management.

AB - The past 5 years have witnessed an intense period of change in the pharmacotherapy of schizophrenia. Several new antipsychotic agents have become available for clinical use, and more are likely to appear over the next few years. The new agents require that clinicians treating patients with schizophrenia adopt new ways of thinking regarding the pharmacotherapy of this illness. Longer drug trials than have traditionally been used may be required to determine response to the newer agents, and response should be measured across negative symptoms, cognitive symptoms, and broader rehabilitative dimensions. Clozapine has an established role in treatment- resistant schizophrenia. Other new antipsychotics are being used with broader clinical indications. The relative efficacy of these agents, particularly in treatment-refractory patients, remains to be determined. The availability of the newer agents may represent an opportunity to reduce the incidence of tardive dyskinesia and to gain better management of comorbid substance abuse and aggression among schizophrenic patients. Significant cost savings could accrue from more effective disease management.

UR - http://www.scopus.com/inward/record.url?scp=0033040677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033040677&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 12

EP - 17

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 1

ER -